This compound can help eye cells survive short-term oxygen loss, but loses its power if the stress lasts too long.
Scientific Claim
Brosimine B at 10 µM is associated with partial restoration of retinal cell viability during oxygen-glucose deprivation at 3 and 6 hours, but not at 24 hours, indicating a time-dependent protective effect in ischemic conditions.
Original Statement
“After the addition of 10 µM of Brosimine B to OGD cell cultures, cell viability increased after a period of 3 h (107.00% ± 6.20%; ### p < 0.0001) and 6 h (25.00% ± 0.70%; ## p < 0.001), but not 24 h (39.00% ± 1.40%; ns; Interaction:13.00).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study observes temporal associations between treatment and viability outcomes but cannot establish causation or biological reason for the time dependency. 'Associated with' is appropriate.
Evidence from Studies
Supporting (1)
Brosimine B and the biphasic dose-response: insights into hormesis and retinal neuroprotection
At a low dose, Brosimine B helps retinal cells survive short-term oxygen and sugar loss, but this help doesn’t last all day — it fades after 24 hours, which matches the claim.